Adjuvant concurrent docetaxel, epirubicin and cyclophosphamide chemotherapy in breast cancer: The TEC regimen. A retrospective analysis
Journal Title: Journal of Cancer Research & Therapy - Year 2014, Vol 2, Issue 2
Abstract
Background: The use of taxanes and anthracyclines in the adjuvant treatment of primary breast cancer is well established, with benefit in both disease free survival (DFS) and overall survival (OS). Several studies demonstrated that the addition of taxanes to anthracycline-based chemotherapy improves the outcome in either concurrent or sequential schedule. Nowadays, the TAC regimen (docetaxel, doxorubicin and cyclophosphamide) is a standard treatment in both node-positive and high-risk node-negative early breast cancer. Doxorubicin and epirubicin are equivalent, but at similar doses epirubicin appears to have a better side effects profile than doxorubicin in terms of myelosuppression and cardiotoxicity. We conducted a retrospective study to establish the role of TEC (epirubicin) regimen in adjuvant setting. Methods: Pre- or post-menopausal women, with stage I-III breast cancer, PS ECOG 0-2 and normal left ventricular ejection fraction, were eligible. TEC chemotherapy at median doses of docetaxel 75 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 500 mg/m2 was administered IV on day 1 every three weeks for 6 cycles. The primary endpoint was toxicity; secondary endpoints were DFS and OS. Results: Thirty-three consecutive female patients were retrospectively enrolled. The median age was 57 years old. Eighty eight percentage of patients completed the treatment plan. In 21.2% of cases a dose reduction was performed and these patients needed a chemotherapy interval prolongation. The main side effects were neutropenia G3-4 (21.2%; 95% CI, 9.8-37.5), allergic reaction G3 to docetaxel (6.1%; 95% CI, 1.0-18.6) and febrile neutropenia (3.0%; 95% CI, 0.1-14.0), while cardiotoxicity was absent (95% CI, 0-8.7%). Globally, the percentage of any other severe side effect was very low and no one toxic death was seen. The 3-year DFS and OS were 89.9% (95% CI, 79.0-100) and 93.8% (95% CI, 85.6-100), respectively. Conclusions: As compared to TAC treatment, TEC regimen with epirubicin 60 mg/m2 is feasible and well tolerated adjuvant chemotherapy in breast cancer, with acceptable and manageable toxicity.
Authors and Affiliations
Galdy S, Zenoni D, Galmozzi A, Mauri CM, Cazzaniga S
Keywords
Related Articles
- EP ID EP547320
- DOI 10.14312/2052-4994.2014-6
- Views 59
- Downloads 0
Decitabine is more cost effective than cytarabine and daunorubicin in elderly acute myeloid leukemia patients
Introduction: Decitabine is not approved in the United States (US) for acute myeloid leukemia (AML) because it did not improve overall survival compared with standard conventional induction treatment with cytarabine and...
Cancer estimation of incidence and survival in Algeria 2014
Cancer is one of the major public health problems in Algeria. In the last 25 years, a significant increase in the incidence of the major types of cancers has been observed in both sexes. Moreover, the 5-year survival rat...
Variability in the induction of alkaline phosphatase by histone deacetylase inhibitors in bladder and colon cancer cell lines
Induction of alkaline phosphatase activity has provided a convenient marker for differentiation of colon cancer cells. The degree to which different histone deacetylase inhibitors induce alkaline phosphatase and dipeptid...
Quantitative assessment of quality of life in New Zealand prostate cancer survivors: the effect of androgen deprivation therapy
Men with prostate cancer experience many challenges to their quality of life (QOL). While some of these challenges reflect the direct effects of the cancer, additional side-effects and symptoms are also associated with c...
A single center series highlights on incidence and management of gastric neuroendocrine tumours with literature review
Neuroendocrine tumours of the digestive system (GEP-NET) are relatively rare. Nevertheless, their diagnoses is rising as seen from studies in the US and elsewhere. Gastric neuroendocrine tumours (Gastric NETs) vary throu...